Previous 10 | Next 10 |
Trevi Therapeutics (TRVI +9.8%) completed enrollment in its phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for pruritus associated with prurigo nodularis (PN). PN is a chronic inflammatory skin disease where an extremely itchy rash appears on parts of the body. The company expects to ...
Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN Top-Line Data Expected 2Q 2022 PR Newswire NEW HAVEN, Conn. , Feb. 1, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmace...
Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications Phase 2 CANAL (Chronic Cough in IPF) Planned Interim Statistical Update 1Q 2022, with Top-Line Data 1H 2022 Phase 2b/3 PRISM (Chronic Pruritus in PN) Enrollment to End January 31, 2022, with Top-Line Da...
Trevi Therapeutics to Attend Multiple Conferences in January 2022 11th Annual LifeSci Partners Corporate Access Event, January 5-7 Dermatology Summit, January 7 H.C. Wainwright BIOCONNECT Virtual Conference, January 10-13 Biotech Showcase 2022, January 10-12 and Janu...
Trevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases PR Newswire NEW HAVEN, Conn. , Nov. 15, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company foc...
Trevi Therapeutics, Inc. (TRVI) Q3 2021 Earnings Conference Call November 10, 2021, 04:30 PM ET Company Participants Jennifer Good - President and CEO Bill Forbes - Chief Development Officer Lisa Delfini - CFO Conference Call Participants Nick Rubino - Stifel Rohit Bhasin - Needham & Comp...
Trevi Therapeutics (NASDAQ:TRVI): Q3 GAAP EPS of -$0.34 beats by $0.12. As of September 30, 2021, the Company had total cash and cash equivalents of $29.3 million. Press Release For further details see: Trevi Therapeutics EPS beats by $0.12
Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 90% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2 CANAL (Chronic Cough in IPF) Actively Enrolling, Top-Li...
Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference PR Newswire NEW HAVEN, Conn. , Nov. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercia...
Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021 Conference Call and Webcast to be Held at 4:30 p.m. ET PR Newswire NEW HAVEN, Conn. , Nov. 3, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc....
News, Short Squeeze, Breakout and More Instantly...
Trevi Therapeutics Inc. Company Name:
TRVI Stock Symbol:
NYSE Market:
Trevi Therapeutics Inc. Website:
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events PR Newswire Two abstracts accepted for oral presentation at the 13 th London International Cough Symposium NEW HAVEN, Conn. , July 2, 2024 /PRNewswire/ -- Trevi Therapeutic...
Trevi Therapeutics to Participate in Upcoming Conferences PR Newswire NEW HAVEN, Conn. , May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates PR Newswire Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of...